The investigational glucagon-like peptide-1, once-weekly dulaglutide, appears to control diabetes in relatively recently diagnosed patients better than daily metformin monotherapy, researchers reported here.
eHealthcare Solutions (EHS) manages advertising on this website.
We use cookies to ensure that we give you the best experience on our website.
By continuing, you agree to the use of cookies as per the EHS Privacy Policy